Key Operational Highlights for Q1FY27

  • Company was fastest growing in top 30 Pharma companies in Indian Pharmaceutical Market (IPM) for MAT June-26 and quarter ended June-26
  • Improved IPM rank to 26th in MAT June-26 from 27th in MAT March 2026
  • Renewed EU-GMP certification for Oral Solid Dosage facility at Bhayla plant in May 2026
  • Inaugurated Hormone Facility at Bhayla with EU-GMP certification in June 2026
  • Chronic and sub-chronic therapies contribute ~73.4% of revenue in Q1FY27

New Manufacturing Facility Details

  • Commercialized India's most advanced EU-GMP approved Women's Hormone Manufacturing Facility
  • Facility addresses growing need for women's healthcare including hormonal disorders, fertility care, and menopause management
  • Multi dosage forms including tablets, soft gel capsules, ointments and gels within single specialized ecosystem
  • Incorporates next-generation manufacturing technologies and digital process controls
  • Spread across 1 Lakh sq. ft with annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels

Financial Performance - Q1FY27 Consolidated (₹ Crores)

| Metric | Q1FY27 | Q1FY26 | YoY Change |

| Revenue from Operations | 422.4 | 346.5 | 21.9% |

| Gross Margin | 81.6% | 81.0% | 60 bps |

| Employee Cost | 122.1 | 97.4 | - |

| Other Expenses | 129.7 | 113.5 | - |

| EBITDA | 93.1 | 69.8 | 33.5% |

| EBITDA Margin | 22.0% | 20.1% | 190 bps |

| Depreciation & Amortization | 13.2 | 8.9 | - |

| Other Income | 3.2 | 2.0 | - |

| Finance Cost | 2.7 | 2.0 | - |

| Share in Profit/(loss) in Associate | 0.0 | -0.2 | - |

| Profit before tax | 80.4 | 60.7 | - |

| Tax Expense | 20.3 | 14.5 | - |

| Profit After Tax | 60.1 | 46.2 | 30.1% |

| PAT Margin | 14.2% | 13.3% | 90 bps |

Company Overview & Strategy

  • Follows 3C Philosophy: Culture, Courage, Commitment
  • 18.4% Revenue MAT Growth - fastest growth among top 30 Indian pharma peers
  • Climbed 6 ranks in IPM over 3 years
  • Market share gains through new product launches, geographical expansion, and field force expansion
  • Portfolio mix shifted from 70:30 to 28:72 (Acute:Chronic) from FY13 to FY23
  • Top 5 brands account for ~35% and Top 10 brands account for ~50% of revenue
  • Focus on specialist doctors in urban and semi-urban markets

Manufacturing Capabilities

  • Quality-focused state-of-the-art manufacturing facilities
  • Additional commercial production of 400 Mn tablets commenced on December 22, 2025 at Gujarat Facility

Market Performance

  • Demonstrated 1.9x growth compared to IPM
  • Focus on four key therapy areas in chronic segment

Brand Building & Collaborations

  • "Engine Brands" approach with successful scaling of brands
  • Significant scaling of acquired brands from GSK Pharmaceuticals, ABBOTT India, Sanofi Healthcare, Bayer Zydus Pharma, and Dr. Reddy's Laboratories
  • Strategic collaboration with Ferring Pharmaceuticals, Switzerland for in-licensing arrangement in Women's Healthcare and Urology therapies
  • Investment in La Chandra Pharmalabs Private Limited for backward integration of Hormone API manufacturing

Management Team

Senior Management:

  • Niravkumar Kritikumar Mehta - Managing Director & CEO (2+ decades experience)
  • Ankur Kritikumar Mehta - Joint Managing Director (2+ decades experience)
  • Viral Bhupendrabhai Sitwala - Whole-Time Director (2+ decades experience)
  • Bhavin Naresh Bhagat - Chief Financial Officer (2+ decades experience)
  • Bhaven Shah - President - Commercial (3+ decades experience)
  • Vijay Charlu - President – India Business (3+ decades experience)
  • Sangeeta Thaker - President – Global Business (2+ decades experience)
  • Tejas Kothari - Vice President – Corp. Strategy & Business Development (2+ decades experience)
  • Chetna Prabhatkumar Dharajiya - CS & Compliance Officer (15+ years experience)

Board of Directors:

  • Dr. Kiritkumar Laxmidas Mehta - Chairman and Non-Executive Director
  • Ameetkumar Hiranyakumar Desai - Independent Director (3+ decades experience)
  • Monica Kanuga - Independent Director (3+ decades experience)
  • Shirish Gundopant Belapure - Independent Director (3+ decades experience)
  • Bhaskar Vemban Iyer - Independent Director (3+ decades experience)

ESG Initiatives

  • Solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park spread across 11.9 Acres
  • Environmental protection through tree plantation, distribution of plant saplings, un-ironed clothes initiative
  • Effluent Treatment plant (ETP) at Bhayla Plant for zero liquid discharge
  • Financial assistance for sports and education promotion
  • Blood donation camps organized
  • Employee training increased by 50%
  • 40% female workforce at Solan Plant
  • World Bank Group EDGE Advance Certificate for energy and water saving
  • A+ Credit Rating
  • Serialization and QR Code Technology for anti-counterfeiting

Historical Financial Performance (₹ Crores)

Profit & Loss Statement

| Metric | FY26 | FY25 | FY24 | FY23 |

| Revenue from Operations | 1,403.2 | 1,196.4 | 1,014.5 | 884.1 |

| Gross Margin | 81.4% | 80.2% | 77.6% | 76.1% |

| EBITDA | 293.4 | 240.0 | 154.7 | 128.0 |

| EBITDA Margin | 20.9% | 20.1% | 15.3% | 14.5% |

| Reported PAT | 185.1 | 149.4 | 90.5 | 84.9 |

| Adjusted PAT* | 199.4 | 149.4 | 90.5 | 84.9 |

| Adjusted PAT Margin | 14.2% | 12.5% | 8.9% | 9.6% |

*Excludes one-time statutory impact of New Labor Code ₹19.1 Cr (Post Tax ₹14.3 Cr) in FY26

Balance Sheet (Mar-26)

  • Total Assets: ₹1,205.1 Cr
  • Non-Current Assets: ₹856.8 Cr (Property, plant: ₹291.1 Cr, CWIP: ₹143.1 Cr, Intangible: ₹262.8 Cr)
  • Current Assets: ₹348.3 Cr (Inventories: ₹125.0 Cr, Trade receivables: ₹145.6 Cr)
  • Total Equity: ₹685.7 Cr
  • Non-Current Liabilities: ₹97.1 Cr
  • Current Liabilities: ₹361.2 Cr (Borrowings: ₹142.9 Cr, Trade Payables: ₹147.1 Cr)

Cash Flow (FY26)

  • Net Cash from Operating Activities: ₹229.5 Cr
  • Net Cash from Investing Activities: -₹256.1 Cr
  • Net Cash from Financing Activities: ₹25.3 Cr
  • Net decrease in Cash: -₹1.4 Cr
  • Cash & Cash equivalents at year-end: ₹1.8 Cr